Press releases

2023-03-24 08:00 Lipum AB – Year-end report 2022 Regulatory
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the...
2023-03-23 16:50 Lipum's ongoing clinical phase 1 study proceeds as planned
Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety...
2023-02-07 13:00 Lipum to participate in following upcoming events
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
2022-12-21 08:30 Lipum AB announces the Nomination Committee for the 2023 Annual General Meeting Regulatory
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2023. In accordance with the decision at the Annual...
2022-11-25 08:30 Lipum AB - interim report for the period July-September 2022 Regulatory
Lipum AB has published the interim report for period July-September 2022. Below is a short summary, a complete report (only in Swedish) is available on...
2022-11-07 11:15 Lipum has initiated a Phase 1 clinical study with its drug candidate SOL-116
Lipum AB (publ) announces that the Phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. To date, a...
2022-10-19 17:00 Lipum announces outcome of directed share issue Regulatory
The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on the Directed Share Issue of 2,601,732...
2022-10-12 11:00 Lipum AB – Report from the Extraordinary General Meeting Regulatory
The EGM resolved to approve the Board of Directors’ previous resolution on September 22, 2022 on a directed share issue of 2,601,732 shares, whereby...
2022-09-27 14:45 Lipum gets approval to start Phase 1 clinical trial with drug candidate SOL-116
The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The...
2022-09-22 21:00 Lipum has resolved on a directed share issue of approximately SEK 39 million at a subscription price of SEK 14.99 per share Regulatory MAR
The Directed Share Issue comprises 2,601,732 new shares issued at a subscription price of SEK 14.99 per share, which means that the Company will raise...
PreviousNext

Investor relations